We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

IMMUNOMODULATORS MARKET ANALYSIS

Immunomodulators Market, by Product Type (Immunosuppressants (Calcineurin Inhibitors, Glucocorticoids, Antimetabolites, and Others), Immunostimulants (Vaccines, Antibodies, and Others)), by Application (Oncology, Respiratory, HIV, and Others), by End User (Hospitals, Clinics, and Others), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

  • Published In : Aug 2021
  • Code : CMI4609
  • Pages :179
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Immunomodulators MarketSize and Trends

The global immunomodulators market is estimated to be valued at US$ 91850.0 Million in 2021 and is expected to reach US$ 156378.2 million by 2028, at a CAGR of 7.9% during the forecast period (2021–2028).

Rising prevalence of multiple sclerosis is expected to drive the market growth over the forecast period.

Multiple sclerosis (MS) is the second leading cause of death, after cardiovascular diseases. Rising prevalence of multiple sclerosis is expected to drive the market growth over the forecast period. For instance, according to a report published in the Multiple Sclerosis Journal 2020, MS affected an estimated 2.8 million people around the world (35.9 per 100,000 population). Since 2013, despite the fact that MS has become more common in every part of the world, there are still disparities in prevalence estimates. The average age of diagnosis is 32 years, and the pooled incidence rate across 75 reporting nations is 2.1 per 100,000 people each year. MS affects twice as many women as it does men.

Rising cases of rheumatoid arthritis is expected to boost the market growth.

The number of active clinical trials to develop immunotherapeutic drugs, such as laquinimod, ozanimod, and ponesimod, is expected to drive the global immunomodulators market in the forecast period. Apart from that, the growing need to treat autoimmune diseases such as rheumatoid arthritis is expected to drive demand for immunomodulators. For instance, in 2018, an estimated 400,000 people in the U.K. had rheumatoid arthritis, and an estimated four million people had an autoimmune disease, according to the British Society for Global Immunomodulators.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.